Alembic eyes US scale-up on back of own ANDAs
This article was originally published in Scrip
Executive Summary
Alembic Pharmaceuticals expects to set up its own front end business in the US sometime in 2014-15 once it builds on a basket of "own ANDAs" and will in the meantime nurture its mostly partnered generic programmes.